Gender characteristics of schizophrenia remission

Abstract

BACKGROUND. Currently, it is relevant to study the gender characteristics of the incidence of schizophrenia, the age of onset, the features of the clinical picture and course of the disease, the response to treatment and the tolerability of antipsychotic drugs in patients.

AIM. The aim of the study was to study the clinical and functional characteristics of remission, depending on the gender of patients with schizophrenia.

MATERIAL AND METHODS. 61 outpatient patients with paranoid schizophrenia (28 men and 33 women) were examined at the stage of remission of the disease. Clinical and scale assessment was carried out using the PANSS, PSP, CGI-S, DAI scales.

RESULTS. There were more married women than men. Restriction of professional activity and social contacts was more often observed in male patients. Among patients without disabilities and patients with the 3rd disability group, female persons prevailed, while among patients with the 2nd disability group — men. It was shown that the age of onset of the disease was significantly less in men than in women. The indicator of the severity of the disease on the CGI-S scale during remission corresponded to moderate severity in men and mild severity in women (p <0.05). The severity of residual productive and, especially, negative symptoms is greater in male patients. The level of social and everyday functioning according to PSP is higher for women than for men. Noticeable disorders prevailed in patients of both sexes, however, they were observed more often among men, while women more often than male patients had minor difficulties in certain areas of functioning. The most pronounced differences were found in the degree of impaired functioning in the behavioral sphere. The paranoid type of remission unfavorable with respect to social functioning was more often observed in men. For women, the thymopathic type of remission turned out to be the most favorable from the point of view of compliance and social functioning. Antipsychotics of the first generation were more often prescribed for the paranoid type of remission in both men and women, while therapy with antipsychotics of the second generation was associated with the most favorable remission options for both men (apathetic type) and women (thymopathic type), which correlated with a higher level of social functioning. In general, the level of social functioning was higher when prescribing second-generation antipsychotics, regardless of the gender of patients with schizophrenia.

CONCLUSION. The hypothesis about the best outcome of the disease in the framework of personal and social recovery in women has been confirmed.

Keywords

schizophrenia / gender characteristics / remission / recovery

References

[1] Bergiannaki JD, Kostaras P. Pharmacokinetic and pharmacodynamic effects of psychotropic medications: Differences between sexes. Psychiatriki. 2016;27(2):118–126. DOI: 10.22365/jpsych.2016.272.118.

[2] Bergiannaki J.D., Kostaras P. Pharmacokinetic and pharmacodynamic effects of psychotropic medications: Differences between sexes // Psychiatriki. 2016. Vol. 27. N. 2. Р. 118–126. DOI: 10.22365/jpsych.2016.272.118.

[3] Bucci P, Galderisi S, Mucci A et al. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatr Scand. 2018;38(3):253–266. DOI: 10.1111/acps.12938.

[4] Bucci P., Galderisi S., Mucci A. et al. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition // Acta. Psychiatr. Scand. 2018. Vol. 38. N. 3. Р. 253–266. DOI: 10.1111/acps.12938.

[5] Galderisi S, Rossi A, Rocca P et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res. 2016;175:154–160. DOI: 10.1016/j.schres.2016.04.043.

[6] Galderisi S., Rossi A., Rocca P. et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives // Schizophr. Res. 2016. Vol. 175. Р. 154–160. DOI: 10.1016/j.schres.2016.04.043.

[7] Dorofeikova M, Neznanov N, Petrova N. Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. Psychiatry Research. 2018;262:542‒548. DOI: 10.1016/j.psychres.2017.09.041.

[8] Dorofeikova M., Neznanov N., Petrova N. Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates // Psychiatry Research. 2018. Vol. 262. Р. 542‒548. DOI: 10.1016/j.psychres.2017.09.041.

[9] Crawford M, DeLisi L. Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry. 2016;29(3):211. DOI: 10.1097/YCO.0000000000000243.

[10] Crawford M., DeLisi L. Issues related to sex differences in antipsychotic treatment // Curr. Opin. Psychiatry. 2016. Vol. 29. N. 3. Р. 211. DOI: 10.1097/YCO.0000000000000243.

[11] Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. DOI: 10.1186/s13293-020-00308-5.

[12] Zucker I., Prendergast B.J. Sex differences in pharmacokinetics predict adverse drug reactions in women // Biol. Sex Differ. 2020. Vol. 11. N. 1. Р. 32. DOI: 10.1186/s13293-020-00308-5.

[13] Bobrovnikova AS. Gender differences in the development of schizophrenia. Bulletin of New Medical Technologies. 2015;4:34. DOI: 10.12737/16776.

[14] Bobrovnikova A.S. Gender differences in the development of schizophrenia // Bulletin of New Medical Technologies. 2015. Vol. 4. Р. 34. DOI: 10.12737/16776.

[15] Grau N, Rubio-Abadal E, Usall J et al. Influence of cognition, premorbid adjustment and psychotic symptoms on psycho-social functioning in first-episode. Psychiatry Res. 2016;242:157–162. DOI: 10.1016/j.psychres.2016.04.121.

[16] Grau N., Rubio-Abadal E., Usall J. et al. Influence of cognition, premorbid adjustment and psychotic symptoms on psycho-social functioning in first-episode // Psychiatry Res. 2016. Vol. 242. Р. 157–162. DOI: 10.1016/j.psychres.2016.04.121.

[17] Riecher-Rossler A, Butler S, Kulkarni J. Sex and gender differences in schizophrenic psychoses-a critical review. Arch Womens Ment Health. 2018;21:627–648. DOI: 10.1007/s00737-018-0847-9.

[18] Riecher-Rossler A., Butler S., Kulkarni J. Sex and gender differences in schizophrenic psychoses-a critical review // Arch. Womens Ment. Health. 2018. Vol. 21. Р. 627–648. DOI: 10.1007/s00737-018-0847-9.

[19] Dama M, Veru F, Schmitz N et al. Sex differences in clinical and functional outcomes among patients treated in an early intervention service for psychotic disorders: An observational study. Can J Psychiatry. 2019;64:708–717. DOI: 10.1177/0706743719854069.

[20] Dama M., Veru F., Schmitz N. et al. Sex differences in cli-nical and functional outcomes among patients treated in an early intervention service for psychotic disorders: An observational study // Can. J. Psychiatry. 2019. Vol. 64. Р. 708–717. DOI: 10.1177/0706743719854069.

[21] Estancial F, de Azevedo RC, Goldbaum M et al. Psychotropic use patterns: Are there differences between men and women? PLOS One. 2018;13(11):e0207921. DOI: 10.1371/journal.pone.0207921.

[22] Estancial F., de Azevedo R.C., Goldbaum M. et al. Psychotropic use patterns: Are there differences between men and women? // PLOS One. 2018. Vol. 13 N. 11. Р. e0207921. DOI: 10.1371/journal.pone.0207921.

[23] Carpiniello B, Pinna F, Tusconi M et al. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophr Res Treatment. 2012;2012576369:1–8. DOI: 10.1155/2012/576369.

[24] Carpiniello B., Pinna F., Tusconi M. et al. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: Preliminary results of a prospective cohort study // Schizophr. Res. Treatment. 2012. Vol. 2012576369. Р. 1–8. DOI: 10.1155/2012/576369.

[25] Falkenburg J, Tracy DK. Sex and schizophrenia: A review of gender differences. Psychosis. 2014;6:61–69. DOI: 10.1080/17522439.2012.733405.

[26] Falkenburg J., Tracy D.K. Sex and schizophrenia: A review of gender differences // Psychosis. 2014. Vol. 6. Р. 61–69. DOI: 10.1080/17522439.2012.733405.

[27] Feldman R. What is resilience: an affiliative neuroscience approach. World Psychiatry. 2020;19:132–150. DOI: 10.1002/wps.20729.

[28] Feldman R. What is resilience: An affiliative neuroscience approach // World Psychiatry. 2020. Vol. 19. Р. 132–150. DOI: 10.1002/wps.20729.

[29] Giulia MG, Paola B, Armida M et al. Gender differences in clinical and psychosocial features among persons with schizophrenia: A mini review. Front Psychiatry. 2021;12: 789179. DOI: 10.3389/fpsyt.2021.789179.

[30] Giulia M.G., Paola B., Armida M. et al. Gender differences in clinical and psychosocial features among persons with schizophrenia: A mini review // Front. Psychiatry. 2021. Vol. 12. Р. 789179. DOI: 10.3389/fpsyt.2021.789179.

[31] Lange B, Mueller JK, Leweke FM, Bumb JM. How gender affects the pharmacotherapeutic approach to treating psychosis — a systematic review. Expert Opin Pharmacother. 2017;18(4):351–362. DOI: 10.1080/14656566.2017.1288722.

[32] Lange B., Mueller J.K., Leweke F.M., Bumb J.M. How gender affects the pharmacotherapeutic approach to treating psychosis — a systematic review // Expert Opin. Pharmacother. 2017. Vol. 18. N. 4. Р. 351–362. DOI: 10.1080/14656566.2017.1288722.

[33] Nordgaard J, Revsbech R, Henriksen MG. Self-disorders, neurocognition, and rationality in schizophrenia: A preliminary study. Psychopathology. 2015;48:310–316. DOI: 10.1080/14656566.2017.1288722.

[34] Nordgaard J., Revsbech R., Henriksen M.G. Self-disorders, neurocognition, and rationality in schizophrenia: A preliminary study // Psychopathology. 2015. Vol. 48. Р. 310–316. DOI: 10.1080/14656566.2017.1288722.

[35] Mosolov SN, Potapov AV, Shafarenko AA et al. Development and validation of standardized criteria for therapeutic remission in schizophrenia. Modern Therapy of Mental Disorders. 2011;3:2–6. (In Russ.)

[36] Мосолов С.Н., Потапов А.В., Шафаренко А.А. и др. Разработки и валидизация стандартизированных критериев терапевтической ремиссии при шизофрении // Современная терапия психических расстройств. 2011. Т. 3. С. 2–6.

[37] Andreasen NC, Carpenter WTJr, Kane JM et al. Remission in schizophrenia: proposed criteria and rational for consensus. Am J Psychiatry. 2005;162:441–449. DOI: 10.1176/appi.ajp.162.3.441.

[38] Andreasen N.C., Carpenter W.T.Jr., Kane J.M. et al. Remission in schizophrenia: Proposed criteria and rational for consensus // Am. J. Psychiatry. 2005. Vol. 162. P. 441–449. DOI: 10.1176/appi.ajp.162.3.441.

[39] Ran MS, Mao WJ, Chan CL et al. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br J Psychiatry. 2015;206:283–288. DOI: 10.1192/bjp.bp.113.139733.

[40] Ran M.S., Mao W.J., Chan C.L. et al. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study // Br. J. Psychiatry. 2015. Vol. 206. P. 283–288. DOI: 10.1192/bjp.bp.113.139733.

[41] Ochoa S, Usall J, Cobo J et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treat. 2012;2012:916198. DOI: 10.1155/2012/916198.

[42] Ochoa S., Usall J., Cobo J. et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review // Schizophr. Res. Treat. 2012. Vol. 2012. Р. 916198. DOI: 10.1155/2012/916198.

[43] Hanlon MC, Campbell LE, Single N et al. Men and women with psychosis and the impact of illness-duration on sex-differences: the second Australian national survey of psychosis. Psychiatry Res. 2017;256:130–143. DOI: 10.1016/j.psychres.2017.06.024.

[44] Hanlon M.C., Campbell L.E., Single N. et al. Men and women with psychosis and the impact of illness-duration on sex-differences: the second Australian national survey of psychosis // Psychiatry Res. 2017. Vol. 256. P. 130–143. DOI: 10.1016/j.psychres.2017.06.024.

[45] Belousov YuB, Zyryanov SK, Belousov DY. Multifactorial clinical and economic analysis of the effectiveness of the use of modern atypical antipsychotics in patients with schizophrenia. High-Quality Clinical Practice. 2011;(1):51–57 (In Russ.)

[46] Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю. Мультифакторный клинико-экономический анализ эффективности применения современных атипичных антипсихотиков у больных с шизофренией // Качественная клиническая практика. 2011. №1. С. 51–57.

[47] Gurovich IYa, Shmukler AB, Dorodnova AS, Kalashnikova II. The resocializing effect of antipsychotics in the complex therapy of patients with newly emerging psychotic conditions. Social and clinical psychiatry. 2011;21(1):43–48 (In Russ.)

[48] Гурович И.Я., Шмуклер А.Б., Дороднова А.С., Калашникова И.И. Ресоциализирующий эффект антипсихотиков в комплексной терапии больных с впервые возникшими психотическими состояниями // Социальная и клиническая психиатрия. 2011. Т. 21. №1. С. 43–48.

[49] Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: Focus on amisulpride. Curr Med Res Opin. 2010;26(4):787–801. DOI: 10.1185/03007990903576953.

[50] Nuss P., Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride // Curr. Med. Res. Opin. 2010. Vol. 26. N. 4. P. 787–801. DOI: 10.1185/03007990903576953.

RIGHTS & PERMISSIONS

Eco-Vector